Clinical Trial

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Study acronym: NEO-MIMAJOR
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is an open-label, randomized, comparative phase III study, which will include subjects with resectable stage III skin melanoma (up to 3 resectable transient metastases are acceptable).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-02-21; most recent amendment 2025-07-07.
Status change: Recruiting → Active, Not Recruiting 2025-07-07
Trial Details
NCT Number NCT05751928
Lead Sponsor Biocad
Conditions Melanoma Stage III, Melanoma (Skin)
Enrollment 411 participants
Start Date 2023-04-05
Primary Completion 2027-01 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-07-08